Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study

José Carlos Bouso, Débora González, Sabela Fondevila, Marta Cutchet, Xavier Fernández, Paulo César Ribeiro Barbosa, Miguel Ángel Alcázar-Córcoles, Wladimyr Sena Araújo, Manel J Barbanoj, Josep Maria Fábregas, Jordi Riba, José Carlos Bouso, Débora González, Sabela Fondevila, Marta Cutchet, Xavier Fernández, Paulo César Ribeiro Barbosa, Miguel Ángel Alcázar-Córcoles, Wladimyr Sena Araújo, Manel J Barbanoj, Josep Maria Fábregas, Jordi Riba

Abstract

Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North America. Members of these groups typically ingest ayahuasca at least twice per month. Prior research has shown that acute ayahuasca increases blood flow in prefrontal and temporal brain regions and that it elicits intense modifications in thought processes, perception and emotion. However, regular ayahuasca use does not seem to induce the pattern of addiction-related problems that characterize drugs of abuse. To study the impact of repeated ayahuasca use on general psychological well-being, mental health and cognition, here we assessed personality, psychopathology, life attitudes and neuropsychological performance in regular ayahuasca users (n = 127) and controls (n = 115) at baseline and 1 year later. Controls were actively participating in non-ayahuasca religions. Users showed higher Reward Dependence and Self-Transcendence and lower Harm Avoidance and Self-Directedness. They scored significantly lower on all psychopathology measures, showed better performance on the Stroop test, the Wisconsin Card Sorting Test and the Letter-Number Sequencing task from the WAIS-III, and better scores on the Frontal Systems Behavior Scale. Analysis of life attitudes showed higher scores on the Spiritual Orientation Inventory, the Purpose in Life Test and the Psychosocial Well-Being test. Despite the lower number of participants available at follow-up, overall differences with controls were maintained one year later. In conclusion, we found no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Schultes RE, Hofmann A (1979) Plants of the Gods: Origins of hallucinogenic use. New York: McGraw-Hill. 192 p.
    1. Tupper KW (2008) The globalization of ayahuasca: Harm reduction or benefit maximization? Int J Drug Policy 19: 297–303.
    1. Labate BC, Santana I, Santos RG (2008) Ayahuasca religions. A comprehensive bibliography & critical essays. Santa Cruz, CA: MAPS. 160 p.
    1. Instituto Nacional de Cultura, Perú (2008) Declaración Patrimonio Cultural de la nación a los conocimientos y usos tradicionales del Ayahuasca practicados por comunidades nativas amazónicas. RESOLUCIÓN DIRECTORAL NACIONAL N° 836/INC.
    1. McKenna DJ (2004) Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 102: 111–129.
    1. International Narcotics Control Board. 2010. Report 2010. Available: . Accessed: 2012 March 2.
    1. Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75: 17–33.
    1. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (2011) Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 493: 76–79.
    1. McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA (2011) Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomed Chromatogr 25: 970–984.
    1. Riba J, Valle M, Urbano G, Yritia M, Morte A, et al. (2003) Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306: 73–83.
    1. dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez-Espinosa J, et al. (2011) Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol 31: 717–726.
    1. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, et al. (2001) Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl) 154: 85–95.
    1. Riba J, Anderer P, Morte A, Urbano G, Jané F, et al. (2002) Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol Jun 53: 613–28.
    1. dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, et al. (2012) Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl) 219: 1039–53.
    1. Camí J, Farré M (2003) Drug addiction. N Engl J Med 349: 975–86.
    1. McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D (2006) The Addiction Severity Index at 25: origins, contributions and transitions. Am J Addict 15: 113–24.
    1. Pierce PA, Peroutka SJ (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97: 118–122.
    1. Smith RL, Canton H, Barrett RJ, Sanders-Bush E (1998) Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol Biochem Behav 61: 323–330.
    1. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101: 131–81.
    1. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14: 295–314.
    1. Vollenweider FX, Vontobel P, Hell D, Leenders KL (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–a PET study with [11C]raclopride. Neuropsychopharmacology 20: 424–33.
    1. Riba J, Romero S, Grasa E, Mena E, Carrió I, et al. (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) 186: 93–98.
    1. Fábregas JM, González D, Fondevila S, Cutchet M, Fernández X, et al. (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 111: 257–61.
    1. Santos RG, Strassman RJ (2008) Ayahuasca and Psychosis. Br J Psychiatry (Online), 3 December. Available: . Accessed: 2012 March 2.
    1. Lima F, Naves M, Motta J, Migueli J, Brito G, et al. (2002) Sistema de Monitoramento Psiquiátrico em Usuários do Chá Hoasca. Rev Bras Psiquiatr 24 (Suppl 2). Available: . Accessed: 2012 March 2.
    1. de Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, et al. (2011) Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Hum Brain Mapp. doi: 10.1002/hbm.21381.
    1. Béïque JC, Imad M, Mladenovic L, Gingrich JA, Andrade R (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A. 104: 9870–9875.
    1. Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, et al. (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184: 86–94.
    1. Da Silveira DX, Grob CS, de Rios MD, Lopez E, Alonso LK, et al. (2005) Ayahuasca in adolescence: a neuropsychological assessment. J Psychoactive Drugs 37: 129–133.
    1. Doering-Silveira E, Lopez E, Grob CS, de Rios MD, Alonso LK, et al. (2005) Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoactive Drugs. 37: 123–128.
    1. Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ (2008) Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 14: SR15–22.
    1. Bouso JC, Riba J (2011) An overview of the literature on the pharmacology and neuropsychiatric long term effects of ayahuasca. In: Santos R.G. (Ed.): The ethnopharmacology of ayahuasca. Kerala, India: Transworld Research Network. pp: 55–63. Ebook. Available: . Accessed: 2012 March 2.
    1. MacRae E (1992) Guided by the moon. Shamanism and the ritual use of ayahuasca in the Santo Daime religion in Brazil. Ebook Available: . Accessed: 2012 March 2.
    1. Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975–990.
    1. Fuentes D, Tavares H, Camargo CHP, Gorenstein C (2000) Inventário de Temperamento e de Carácter de Cloninger – Validação da versão em Português. In: Escalas de Avaliação Clínica em Psiquiatria e Psicofarmacologia. pp. 363–369.
    1. Derogatis LR (1994) SCL-90-R. Symptom Checklist-90-R. Administration, scoring and procedures manual. Minneapolis: National Computer System. 123 p.
    1. Tosello D (2001) Escala de avaliação de Sintomas-90-R, SCL-90-R: Adaptação, precisão e validade. Doctoral Dissertation. Universidade Católica de Campinas. Brazil. 95 p.
    1. Golden CJ (1994) Stroop, test de colores y palabras. Madrid: TEA. 46 p.
    1. Melcher T, Falkai P, Gruber O (2008) Functional brain abnormalities in psychiatric disorders: neural mechanisms to detect and resolve cognitive conflict and interference. Brain Res Rev 59: 96–124.
    1. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G (2001) Test de Clasificación de Tarjetas de Wisconsin. Madrid: TEA Ediciones. 72 p.
    1. Strauss E, Sherman EMS, Spreen O (2006) A compendium of neuropsychological tests: Administration, norms, and commentary. Oxford; New York: Oxford University Press. 1216 p.
    1. Nyhus E, Barceló F (2009) The Wisconsin Card Sorting Test and the cognitive assessment of prefrontal executive functions: A critical update. Brain Cogn 71: 437–451.
    1. Wechsler D (1997) Wechsler Adult Intelligence Scale –Third Edition. San Antonio: The Psychological Corporation.
    1. Barbey AK, Koenigs M, Grafman J (2011) Orbitofrontal contributions to human working memory. Cereb Cortex 21: 789–795.
    1. Grace J, Malloy PF (2001) FrSBe. Frontal Systems Behavior Scale. Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc. 110 p.
    1. Elkins DN, Hedstrom LJ, Hughes LL, Leaf JA, Saunders C (1988) Toward phenomenological spirituality: Definition, description, and measurement. J Humanist Psychol 28: 5–18.
    1. Crumbaugh JC, Maholick LT (1976) The purpose in life test. Murfreesboro, TN: Psychometric Affiliates.
    1. Casullo MM, Castro A (2000) Evaluación del bienestar psicológico en estudiantes adolescentes argentinos. Revista de Psicología. Pontificia Universidad Católica del Perú XVIII: 35–68.
    1. Cloninger CR, Przybeck TR, Svrakic DM, Wttzel RD (1994) The Temperament and Character Inventory (T.C.I.): A guide to its development and use. St. Louis (MO): Washington University. 184 p.
    1. Pedrero-Pérez EJ (2006) Diferencias de personalidad entre adictos a sustancias y población general. Estudio con el TCI-R de casos clínicos con controles emparejados. Adicciones 18: 135–148.
    1. Verdejo-García A, Lawrence AJ, Clark L (2008) Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 32: 777–810.
    1. Barbosa PC, Cazorla IM, Giglio JS, Strassman R (2009) A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects. J Psychoactive Drugs 41: 205–212.
    1. MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.
    1. Stenner K (2005) The Authoritarian Dynamic. New York: Cambridge University Press. 370 p.
    1. Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr (2005) Psychological and cognitive effects of long-term peyote use among Native Americans Biol Psychiatry. 58: 624–631.
    1. Barbosa PC, Giglio JS, Dalgalarrondo P (2005) Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs 37: 193–201.
    1. Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz AP (2007) Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol 112: 507–513.
    1. Derogatis LR (2001) Cuestionario de 90 síntomas (SCL-90-R). Madrid: TEA Ediciones, S.A. 21 p.
    1. Goldberg E (2001) The executive brain: Frontal lobes and the civilized mind. NY: Oxford University Press. 251 p.
    1. Tekin S, Cummings JL (2002) Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 53: 647–654.
    1. Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24: 167–202.
    1. Colzato LS, Huizinga M, Hommel B (2009) Recreational cocaine polydrug use impairs cognitive flexibility but not working memory. Psychopharmacology (Berl) 207: 225–34.
    1. Le Berre AP, Pinon K, Vabret F, Pitel AL, Allain P, et al. (2010) Study of metamemory in patients with chronic alcoholism using a feeling-of-knowing episodic memory task. Alcohol Clin Exp Res 34: 1888–1898.
    1. Fernández-Serrano MJ, Perales JC, Moreno-López L, Pérez-García M, Verdejo-García A (2012) Neuropsychological profiling of impulsivity and compulsivity in cocaine dependent individuals. Psychopharmacology (Berl) 219: 673–683.
    1. Nestor LJ, Ghahremani DG, Monterosso J, London ED (2011) Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects Psychiatry Res. 194: 287–295.
    1. Fernández-Serrano MJ, Pérez-García M, Schmidt Río-Valle J, Verdejo-García A (2010) Neuropsychological consequences of alcohol and drug abuse on different components of executive functions. J Psychopharmacol. 24: 1317–1332.
    1. Yücel M, Lubman DI, Solowij N, Brewer WJ (2007) Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry 41: 957–968.
    1. Jocham G, Ullsperger M (2009) Neuropharmacology of performance monitoring. Neurosci Biobehav Rev 33: 48–60.
    1. Lane HY, Liu YC, Huang CL, Hsieh CL, Chang YL, et al. (2008) Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults. J Psychiatry Neurosci 33: 47–53.
    1. Passetti F, Dalley JW, Robbins TW (2003) Double dissociation of serotonergic and dopaminergic mechanisms on attentional performance using a rodent five-choice reaction time task. Psychopharmacology (Berl). 165: 136–145.
    1. Williams GV, Srinivas GR, Goldman-Rakic PS (2002) The pshysiological role of the 5-HT2A in working memory. J Neurosci 22: 2843–54.
    1. Macher RB, Earleywine M (2012) Enhancing neuropsychological performance in chronic cannabis users: The role of motivation. J Clin Exp Neuropsychol. DOI: 10.1080/13803395.2011.646957.
    1. Spinella M (2003) Relationship between drug use and prefrontal-associated traits. Addict Biol 8: 67–74.
    1. Verdejo-García A, Rivas-Pérez C, López-Torrecillas F, Pérez-García M (2006) Differential impact of severity of drug use on frontal behavioral symptoms. Addict Behav 31: 1373–1382.
    1. Verdejo-García A, Bechara A, Recknor EC, Pérez-García M (2006) Executive dysfunction in substance dependent individuals during drug use and abstinence: An examination of the behavioral, cognitive and emotional correlates of addiction. J Int Neuropsychol Soc 12: 405–415.
    1. Trichter S, Klimo J, Krippner S (2009) Changes in spirituality among ayahuasca ceremony novice participants. J Psychoactive Drugs 41: 121–34.
    1. Francis L, Kaldor P (2001) The relationship between religion and purpose in life in an Australian Population Survey. Res Soc Sci Stud Relig 12: 53–63.
    1. Oberauer K, Schulze R, Wilhelm O, Süss HM (2005) Working memory and intelligence–their correlation and their relation: comment on Ackerman, Beier, and Boyle. Psychol Bull 131: 61–65; author reply 72–75.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する